FN1 and metastatic neoplasm: Thus, if we can inhibit mesothelial conversion to OCAMs or inhibit the FN1/Akt signaling pathway axis, we may be able to effectively control the development of peritoneal metastatic tumors even with the use of conventional platinum‐based chemotherapy.